SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial

Launched by NOVO NORDISK A/S · Jul 13, 2021

Keywords

ClinConnect Summary

The SELECT-LIFE study is a research project designed to look at the long-term effects of a medication called semaglutide in people who participated in a previous study known as the SELECT trial. This new study will begin after the SELECT trial ends and will last for up to 10 years. Participants will be asked to complete a health questionnaire every six months to help researchers understand how the medication affects their health over time. It's important to note that once the SELECT trial is over, participants will not receive any medication or treatment from the SELECT-LIFE study; they will continue to be cared for by their own doctors.

To be eligible for the SELECT-LIFE study, participants must have been enrolled in the SELECT trial and have not withdrawn their consent. This means they participated in the SELECT trial and agreed to take part in this follow-up study. However, individuals who have mental health issues that prevent them from understanding the study or who are unwilling to participate cannot join. Overall, the SELECT-LIFE study aims to gather valuable information about the long-term impact of semaglutide on health, helping future patients and healthcare providers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Randomized into the SELECT clinical trial (EX9536-4388) and has not withdrawn consent, regardless of level of participation, dose achieved or treatment discontinuation.
• • Signed SELECT-LIFE consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
• Exclusion criteria:
• • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation